X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs DR. REDDYS LAB - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA DR. REDDYS LAB SUN PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 42.8 26.2 163.4% View Chart
P/BV x 3.3 3.2 102.8% View Chart
Dividend Yield % 0.4 0.8 46.6%  

Financials

 SUN PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
DR. REDDYS LAB
Mar-18
SUN PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs7012,788 25.1%   
Low Rs4331,902 22.8%   
Sales per share (Unadj.) Rs110.4860.8 12.8%  
Earnings per share (Unadj.) Rs11.057.1 19.2%  
Cash flow per share (Unadj.) Rs17.2122.0 14.1%  
Dividends per share (Unadj.) Rs2.0020.00 10.0%  
Dividend yield (eoy) %0.40.9 41.4%  
Book value per share (Unadj.) Rs158.8757.7 21.0%  
Shares outstanding (eoy) m2,399.26165.91 1,446.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x5.12.7 188.5%   
Avg P/E ratio x51.641.1 125.7%  
P/CF ratio (eoy) x32.919.2 171.2%  
Price / Book Value ratio x3.63.1 115.3%  
Dividend payout %18.235.0 52.0%   
Avg Mkt Cap Rs m1,360,021389,034 349.6%   
No. of employees `00017.823.5 75.6%   
Total wages/salary Rs m53,67132,149 166.9%   
Avg. sales/employee Rs Th14,890.96,070.8 245.3%   
Avg. wages/employee Rs Th3,017.11,366.6 220.8%   
Avg. net profit/employee Rs Th1,480.6402.5 367.9%   
INCOME DATA
Net Sales Rs m264,895142,810 185.5%  
Other income Rs m8,3881,552 540.4%   
Total revenues Rs m273,282144,362 189.3%   
Gross profit Rs m56,08123,512 238.5%  
Depreciation Rs m14,99810,772 139.2%   
Interest Rs m5,176788 656.8%   
Profit before tax Rs m44,29513,504 328.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m0344 0.0%   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,4524,380 193.0%   
Profit after tax Rs m26,3389,468 278.2%  
Gross profit margin %21.216.5 128.6%  
Effective tax rate %19.132.4 58.8%   
Net profit margin %9.96.6 150.0%  
BALANCE SHEET DATA
Current assets Rs m316,359104,984 301.3%   
Current liabilities Rs m198,64368,938 288.1%   
Net working cap to sales %44.425.2 176.1%  
Current ratio x1.61.5 104.6%  
Inventory Days Days9574 127.5%  
Debtors Days Days108104 104.0%  
Net fixed assets Rs m213,178104,385 204.2%   
Share capital Rs m2,399830 289.1%   
"Free" reserves Rs m378,606124,886 303.2%   
Net worth Rs m381,006125,716 303.1%   
Long term debt Rs m17,72125,089 70.6%   
Total assets Rs m643,028225,443 285.2%  
Interest coverage x9.618.1 52.7%   
Debt to equity ratio x00.2 23.3%  
Sales to assets ratio x0.40.6 65.0%   
Return on assets %4.94.5 107.7%  
Return on equity %6.97.5 91.8%  
Return on capital %10.09.7 103.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m40,81672,623 56.2%   
Fx outflow Rs m30,14318,916 159.4%   
Net fx Rs m10,67353,707 19.9%   
CASH FLOW
From Operations Rs m39,07218,030 216.7%  
From Investments Rs m-33,708-14,883 226.5%  
From Financial Activity Rs m-15,393-4,440 346.7%  
Net Cashflow Rs m-7,359-1,236 595.4%  

Share Holding

Indian Promoters % 63.7 25.5 249.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 5.4 95.0%  
FIIs % 23.0 35.3 65.2%  
ADR/GDR % 0.0 18.5 -  
Free float % 8.3 15.3 54.2%  
Shareholders   133,026 75,885 175.3%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   IPCA LABS  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA LTD  NOVARTIS  

Compare SUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 300 Points Lower; Metal and IT Stocks Witness Selling(Closing)

Share markets in India witnessed most of the selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 19, 2018 | Updated on Sep 19, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Nov 20, 2018 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - SANOFI INDIA COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS